FARXIGA in Primary Care

NEW INDICATION: The first therapy approved in 20 years to help delay the worsening of CKD in patients at risk of progression, with and without T2D.1

Protect life: FARXIGA is proven to help protect your patients with CKD at risk of progression against worsening kidney function, ESKD, CV death, and hospitalization for heart failure—so they can live life.1

For your CKD patients who have T2D and an eGFR <60 mL/min/1.73 m2, early intervention is critical because lost kidney function is rarely recovered3

You’ve probably seen this patient. He presents with T2D and an eGFR <60 mL/min/1.73 m2. And he’s currently on a glycemic-lowering agent as well as receiving CKD standard of care (ACEI or ARB).

Adults with CKD are 5x more likely to die from a CV event than to develop ESKD4

Two Leading Causes of CKDTwo Leading Causes of CKD

What can you do to provide the early intervention needed to limit irreversible kidney damage?


ACEI=angiotensin-converting enzyme inhibitor; ARB=angiotensin II receptor blocker; CKD=chronic kidney disease; CV=cardiovascular; eCVD=established cardiovascular disease; eGFR=estimated glomerular filtration rate; ESKD=end-stage kidney disease; HFrEF=heart failure with reduced ejection fraction; T2D=type 2 diabetes.

CKD=chronic kidney disease; CV=cardiovascular; eCVD=established cardiovascular disease; eGFR=estimated glomerular filtration rate; ESKD=end-stage kidney disease; HFrEF=heart failure with reduced ejection fraction; T2D=type 2 diabetes.

IMPORTANT SAFETY INFORMATION FOR FARXIGA